新华时评：严查！斩断回流药黑色链条

Core Viewpoint - The National Medical Insurance Administration has launched a campaign to combat the illegal sale and circulation of counterfeit drugs, emphasizing the importance of drug traceability to ensure public health and safety [1][2]. Group 1: Drug Traceability and Regulation - The campaign showcases the effectiveness of "code-based supervision" in tackling the issue of counterfeit drugs, which are often sourced through illegal channels and pose significant health risks to patients [1]. - Starting from July 1, all medical insurance designated institutions are required to scan the unique "electronic ID" traceability code of each drug box, allowing for tracking of drug sources and destinations [1]. Group 2: Challenges and Responsibilities - Despite the regulatory efforts, some illegal actors continue to profit from the distribution of non-compliant drugs, indicating that a comprehensive approach is necessary to eliminate the entire chain of illegal activities [2]. - Pharmaceutical companies, medical institutions, and retail pharmacies must adhere to strict drug sales management to prevent drugs from entering non-regulated channels, while the public should be aware of the risks and refrain from participating in the illegal sale of medical insurance drugs [2].